Karl, A. ; Buchner, A. 
; Tympner, C. ; Kirchner, T. ; Ganswindt, U. ; Belka, C. ; Ganzer, R. ; Burger, M. ; Eder, F. ; Hofstädter, F. ; Schilling, D. ; Sievert, K. ; Stenzl, A. ; Scharpf, M. ; Fend, F. ; vom Dorp, F. ; Rübben, H. ; Schmid, K. ; Porres-Knoblauch, D. ; Heidenreich, A. ; Hangarter, B. ; Knüchel-Clarke, R. ; Rogenhofer, M. ; Wullich, B. ; Hartmann, A. ; Comploj, E. ; Pycha, A. ; Hanspeter, E. ; Pehrke, D. ; Sauter, G. ; Graefen, M. ; Stief, C. ; Haese, A.
; Tympner, C. ; Kirchner, T. ; Ganswindt, U. ; Belka, C. ; Ganzer, R. ; Burger, M. ; Eder, F. ; Hofstädter, F. ; Schilling, D. ; Sievert, K. ; Stenzl, A. ; Scharpf, M. ; Fend, F. ; vom Dorp, F. ; Rübben, H. ; Schmid, K. ; Porres-Knoblauch, D. ; Heidenreich, A. ; Hangarter, B. ; Knüchel-Clarke, R. ; Rogenhofer, M. ; Wullich, B. ; Hartmann, A. ; Comploj, E. ; Pycha, A. ; Hanspeter, E. ; Pehrke, D. ; Sauter, G. ; Graefen, M. ; Stief, C. ; Haese, A. 
Abstract
To predict biochemical recurrence respecting the natural course of pT2 prostate cancer with positive surgical margin (R1) and no adjuvant/neoadjuvant therapy. A multicenter data analysis of 956 patients with pT2R1N0/Nx tumors was performed. Patients underwent radical prostatectomy between 1994 and 2009. No patients received neoadjuvant or adjuvant therapy. All prostate specimens were re-evaluated ...
Owner only: item control page
Altmetric